Quantitation of Monophosphorylated Lipid A in the Oil-in-Water Adjuvant Delivery Systems Using Transesterification and GC-MS

2017 ◽  
Vol 106 (7) ◽  
pp. 1760-1763
Author(s):  
M. Athar Masood ◽  
Josip Blonder ◽  
Timothy D. Veenstra
Keyword(s):  
Lipid A ◽  
Delivery Systems ◽  
Oil In Water

scholarly journals Fucoxanthin-Loaded Oil-in-Water Emulsion-Based Delivery Systems: Effects of Natural Emulsifiers on the Formulation, Stability, and Bioaccessibility

ACS Omega ◽  
2019 ◽  
Vol 4 (6) ◽  
pp. 10502-10509 ◽  
Author(s):  
Zhaoxiang Ma ◽  
Nauman Khalid ◽  
Gaofeng Shu ◽  
Yiguo Zhao ◽  
Isao Kobayashi ◽  
...  
Keyword(s):  
Delivery Systems ◽  
Water Emulsion ◽  
Oil In Water ◽  
Oil In Water Emulsion ◽  
Formulation Stability

Chia seed oil-in-water emulsions as potential delivery systems of ω-3 fatty acids

2015 ◽  
Vol 162 ◽  
pp. 48-55 ◽  
Author(s):  
Luciana Magdalena Julio ◽  
Vanesa Yanet Ixtaina ◽  
Mariela Alejandra Fernández ◽  
Rosa Maria Torres Sánchez ◽  
Jorge Ricardo Wagner ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Seed Oil ◽  
Delivery Systems ◽  
Chia Seed ◽  
Oil In Water ◽  
Chia Seed Oil

Retention and release of oil-in-water emulsions from filled hydrogel beads composed of calcium alginate: impact of emulsifier type and pH

Soft Matter ◽  
2015 ◽  
Vol 11 (11) ◽  
pp. 2228-2236 ◽  
Author(s):  
Benjamin Zeeb ◽  
Amir Hossein Saberi ◽  
Jochen Weiss ◽  
David Julian McClements
Keyword(s):  
Calcium Alginate ◽  
Delivery Systems ◽  
Natural Food ◽  
Food Grade ◽  
Hydrogel Beads ◽  
Hydrogel Particles ◽  
Oil In Water

Delivery systems based on filled hydrogel particles (microgels) can be fabricated from natural food-grade lipids and biopolymers.

scholarly journals Differential Immunogenicity and Protective Efficacy Elicited by MTO- and DMT-Adjuvanted CMFO Subunit Vaccines against Mycobacterium tuberculosis Infection

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Nadeem Ullah ◽  
Ling Hao ◽  
Yaqi Wu ◽  
Yandi Zhang ◽  
Qing Lei ◽  
...  
Keyword(s):  
Delivery System ◽  
Subunit Vaccine ◽  
Lipid A ◽  
Protective Efficacy ◽  
Protein Vaccine ◽  
Subunit Vaccines ◽  
Water Emulsion ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Oil In Water

Tuberculosis (TB) remains a major and global problem of public health. An effective TB subunit vaccine is urgently needed. Proper selection of the delivery system for the vaccine is crucial for inducing an appropriate immune response tailored to control the target pathogen. In this study, we compared the immunogenicity and protective efficacy of CMFO subunit vaccines against primary progressive TB in two different adjuvant systems: the MTO oil-in-water (O/W) emulsion composed of monophosphoryl lipid A (MPL), trehalose-6,60-dibehenate (TDB), and oil in water emulsion MF59 and the DMT liposome containing dimethyldioctadecylammonium bromide (DDA), monophosphoryl lipid A (MPL), and trehalose-6,60-dibehenate (TDB). Our results demonstrated that the DMT-adjuvanted CMFO could confer more significant protection against M. tuberculosis infection than the CMFO/MTO did in mice. In particular, the adjuvant DMT showed a stronger ability than the O/W emulsion to adjuvant CMFO subunit vaccine and enhanced protection, attributed to elicit Th1-biased responses, strong Th1/Th17 cytokine responses, and IFN-γ+ or IL-2+ T cell responses. Therefore, our findings demonstrate that the liposome delivery system shows more effectiveness to adjuvant TB subunit vaccine than O/W emulsion and highlight the importance of adjuvant formulation for the better efficacy of a protein vaccine.

scholarly journals Peptide vaccine with glucopyranosyl lipid A–stable oil-in-water emulsion for patients with resected melanoma

Immunotherapy ◽  
2020 ◽  
Vol 12 (13) ◽  
pp. 983-995
Author(s):  
Eric P Grewal ◽  
Courtney L Erskine ◽  
Wendy K Nevala ◽  
Jacob B Allred ◽  
Carrie A Strand ◽  
...  
Keyword(s):  
T Cells ◽  
Lipid A ◽  
Peptide Vaccine ◽  
Clinical Trial Registration ◽  
Water Emulsion ◽  
Risk Melanoma ◽  
Oil In Water ◽  
Grade 3 ◽  
Resected Stage ◽  
Oil In Water Emulsion

Aim: We tested the safety and immunogenicity of a novel vaccine in patients with resected high-risk melanoma. Patients & methods: HLA-A2-positive patients with resected Stage II–IV melanoma were randomized to receive up to three vaccinations of melanoma-associated peptide (MART-1a) combined with a stable oil-in-water emulsion (SE) either with the Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA-SE–Schedule 1) or alone (SE–Schedule 2). Safety and immunogenicity of the vaccines were monitored. Results: A total of 23 patients were registered. No treatment-related grade 3 or higher adverse events were observed. Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. Conclusion: Both vaccine schedules were well-tolerated and resulted in an increase in MART-1a-specific T cells. Clinical Trial registration: NCT02320305 ( ClinicalTrials.gov ).

Sign in / Sign up

Export Citation Format

Share Document